Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session
Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe…
From Phase III Trials to Commercialization Partnerships, MindRank’s AI Drug Development Value Comes into Focus
TMX Group Equity Financing Statistics – September 2026
TMX Group Limited Announces Release Date for Q3 2026 Financial Results and Analyst Conference Call
GMG Announces 48% Increase in Energy Density, Doubling of Cycle Life and 94% Energy Efficiency for 6 Minute Fast Charge
DGTL Holdings Inc. Announces Failure-to-File Cease Trade Order